Paper2993535
High-dose cisplatin in hypertonic saline in refractory ovarian cancer.
Ozols RF and 3 others. J Clin Oncol, 1985. Cited by 240 papers, by iCite.
Cite this record
ConductScience Library. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. Papers, record 2993535. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2993535
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Ovarian Neoplasms | Major topic |
| Adult | |
| Aged | |
| Bone Marrow | |
| Drug Evaluation | |
| Female | |
| Humans | |
| Kidney Function Tests | |
| Middle Aged | |
| Nausea | |
| Peripheral Nervous System Diseases | |
| Saline Solution, Hypertonic | |
| Vomiting |
Source PubMed
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 240 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37530985 | Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR. | Cancer Causes Control | 2024 | https://conductscience.org/library/papers/37530985 | PubMed |
| 23788859 | Chemotherapy-induced polyneuropathy. Part I. Pathophysiology. | Contemp Oncol (Pozn) | 2012 | https://conductscience.org/library/papers/23788859 | PubMed |
| 22045362 | Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. | J Natl Cancer Inst | 2011 | https://conductscience.org/library/papers/22045362 | PubMed |
| 19916578 | Cisplatin overdose: toxicities and management. | Drug Saf | 2009 | https://conductscience.org/library/papers/19916578 | PubMed |
| 10864227 | Clinical pharmacokinetics and administration of established platinum drugs. | Drugs | 2000 | https://conductscience.org/library/papers/10864227 | PubMed |
| 9637718 | Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. | J Clin Invest | 1998 | https://conductscience.org/library/papers/9637718 | PubMed |
| 8398709 | Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8398709 | PubMed |
| 8353050 | EPIC: an effective low toxicity regimen for relapsing lymphoma. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8353050 | PubMed |
| 8261575 | Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8261575 | PubMed |
| 8258189 | Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8258189 | PubMed |
| 7981487 | New platinum agents. A comparison in ovarian cancer. | Drugs Aging | 1994 | https://conductscience.org/library/papers/7981487 | PubMed |
| 7850928 | Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7850928 | PubMed |
| 7693428 | New cisplatin analogues in development. A review. | Drugs | 1993 | https://conductscience.org/library/papers/7693428 | PubMed |
| 7692922 | Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours. | Br J Cancer | 1993 | https://conductscience.org/library/papers/7692922 | PubMed |
| 7497577 | Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7497577 | PubMed |
| 3568273 | High-dose cisplatin in advanced head and neck cancer. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3568273 | PubMed |
| 3342465 | Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3342465 | PubMed |
| 3064798 | A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer. | Br J Cancer | 1988 | https://conductscience.org/library/papers/3064798 | PubMed |
| 3049431 | Evolution of high-dose cisplatin. | Invest New Drugs | 1988 | https://conductscience.org/library/papers/3049431 | PubMed |
| 3048763 | Resistance to cisplatin and analogues: mechanisms and potential clinical implications. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3048763 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2993535
GET https://conductscience.org/api/papers/v1/2993535/cited_by?page=2